GRM2 and schizophrenia: Clinical trial studies reported that treatment with the mGluR2/3 agonist LY2140023 led to significant improvements in both positive and negative symptoms in patients with schizophrenia, and its analogue LY379268 (LY37) reversed the behavioral effects in animal models of schizophrenia [7].